Provided by Tiger Trade Technology Pte. Ltd.

Sagimet Biosciences Inc.

9.14
-0.2300-2.45%
Post-market: 9.260.1246+1.36%19:54 EDT
Volume:1.71M
Turnover:15.58M
Market Cap:648.11M
PE:-7.32
High:9.38
Open:9.26
Low:8.88
Close:9.37
52wk High:11.45
52wk Low:4.50
Shares:70.91M
Float Shares:64.53M
Volume Ratio:0.78
T/O Rate:2.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2490
EPS(LYR):-1.5800
ROE:-24.37%
ROA:-16.41%
PB:2.53
PE(LYR):-5.78

Loading ...

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

GlobeNewswire
·
Aug 04

Sagimet, PNC, United Rentals, Rani, Southern Copper Insider Shake-Up

TIPRANKS
·
Jul 25

Top Sagimet Executives Quietly Unlock Major Value in Recent Stock Moves

TIPRANKS
·
Jul 23

Sagimet Biosciences Director George Kemble Disposes of USD 140,548 in Common Shares

Reuters
·
Jul 23

Sagimet Biosciences Added to Russell Indexes

MT Newswires Live
·
Jun 30

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

GlobeNewswire
·
Jun 29

Sagimet Biosciences grants 34,300 inducement stock options to new hires

Reuters
·
Jun 23

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 23

Sagimet: Buy Rating Reiterated as Denifanstat Advances and $28 Price Target Remains Unchanged

TIPRANKS
·
Jun 18

Sagimet Biosciences Announces Board Changes and Director Elections

TIPRANKS
·
Jun 13

Sagimet Biosciences shareholders elect Class III directors at annual meeting

Reuters
·
Jun 13

Sagimet Biosciences Grants New Performance-Based Executive Equity Awards

TIPRANKS
·
Jun 04

Sagimet Biosciences grants CEO David Happel 300,000 stock options, 300,000 performance-based RSUs

Reuters
·
Jun 04

UK's Mhra: Resmetirom (Rezdiffra) Authorised to Treat Metabolic Dysfunction-Associated Steatohepatitis (Mash) in Adults

THOMSON REUTERS
·
Jun 03

Sagimet says Phase 1 trial shows denifanstat-resmetirom combo cuts LDL cholesterol in healthy adults

Reuters
·
May 27

Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

GlobeNewswire
·
May 27

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 27

Sagimet Biosciences Is Maintained at Market Outperform by Citizens

Dow Jones
·
May 19

Sagimet Biosciences price target lowered to $12 from $35 at Citizens

TIPRANKS
·
May 19

Sagimet Biosciences files Form 3 for Chief Medical Officer Andreas Grauer

Reuters
·
May 15